查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1620685

血浆分馏市场：按产品、应用和最终用户划分 - 全球预测 2025-2030 年

Plasma Fractionation Market by Product (Albumin, Coagulation Factor Concentrates, Immunoglobulin), Application (Critical Care, Hemato-Oncology, Hematology), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年血浆分馏市场价值为355.2亿美元，预计到2024年将达到389.5亿美元，复合年增长率为10.45%，到2030年将达到712.7亿美元。

血浆分馏是指分离精製血浆成分的过程，主要用于医疗。这包括免疫球蛋白、白蛋白和凝血因子等蛋白质，它们对于治疗免疫力缺乏、血友病、自体免疫疾病等多种治疗应用至关重要。对血浆分馏的需求源于对血浆衍生疗法的迫切需求，以治疗无法用合成替代品有效治疗的慢性疾病。因此，它的主要用途是作为需要长期治疗的疾病的药物。最终用途领域主要是医院、研究机构和製药公司。市场受到个人化医疗需求不断增长、医疗基础设施进步以及血浆治疗意识不断增强的显着影响。改进的血浆分离纯化工艺和人工智慧在诊断中的整合等技术进步带来了潜在的成长机会。抓住这些机会的主要建议包括投资研发以提高产品效率以及形成策略联盟以简化供应链流程。然而，血浆治疗的高成本、血浆捐献的伦理问题以及一些地区严格的监管要求都是限制因素。此外，由于捐赠者的可用性而导致的血浆供应波动可能会为满足全球需求带来挑战。寻求成长的公司应专注于加强捐助者招募策略和开发可以缓解供应问题的合成或替代蛋白质等领域。创新还可以针对改进分馏技术，以提高产量比率和安全标准。鑑于市场的竞争格局，对监管格局的透彻了解和对技术升级的持续投资对于持续成功至关重要。此外，关注教育和宣传宣传活动可以减轻对捐赠的担忧，并最终支持市场扩张。

主要市场统计
基准年[2023] 355.2亿美元
预计年份 [2024] 389.5亿美元
预测年份 [2030] 712.7亿美元
复合年增长率（%） 10.45%

市场动态：揭示快速发展的血浆分馏市场的关键市场见解

供需的动态交互作用正在改变血浆分馏市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 改善血浆疗法的可及性以及免疫球蛋白在各个治疗领域的高利用率
    • 政府努力增加血浆采集
    • 世界老年人口增加及采血设施增加
  • 市场限制因素
    • 存在对目前病毒灭活治疗具有抗药性的新病原体
  • 市场机会
    • 製程开发技术的不断进步以改进配方
    • 新临床试验的使用迅速增加，活性化血浆疗法的研发活动
  • 市场问题
    • 关于血浆分馏和替代重组疗法的存在的严格政府法规

波特五力：驾驭血浆分馏市场的策略工具

波特的五力架构是了解血浆分馏市场竞争格局的关键工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解血浆分馏市场的外部影响

外部宏观环境因素在塑造血浆分馏市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解血浆分馏市场的竞争格局

血浆分馏市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：血浆分馏市场供应商的绩效评估

FPNV定位矩阵是评估血浆分馏市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製血浆分馏市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，血浆分馏市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开发：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、未开发地区、主要产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 改善血浆治疗的可及性并在各个治疗领域大量使用免疫球蛋白
      • 政府努力增加血浆采集
      • 随着世界各地老年人数量的增加，采血设施的数量也增加。
    • 抑制因素
      • 存在对目前病毒灭活治疗具有抗药性的新病原体
    • 机会
      • 製程开发技术的不断进步以改进配方
      • 在新的临床试验中广泛应用，并扩大血浆治疗的研发活动
    • 任务
      • 关于血浆分馏和替代重组疗法的存在的严格政府法规
  • 市场区隔分析
    • 产品：增加血浆分馏在免疫球蛋白精製的使用
    • 应用：扩大用于治疗血液疾病
    • 最终用户：血浆分馏广泛用于临床实验室，以确保血浆衍生产品的安全性和有效性。
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章血浆分馏市场：副产品

  • 介绍
  • 白蛋白
  • 浓缩凝血因子
    • 因子IX
    • 因子VIII
    • 因子XIII
    • 纤维蛋白原浓缩物
    • 凝血酶原复合物浓缩物
    • 血管性血友病因子
  • 免疫球蛋白
    • 静脉注射免疫球蛋白
    • 皮下注射免疫球蛋白
  • 蛋白酶抑制剂

第七章血浆分馏市场：依应用分类

  • 介绍
  • 加护治疗
  • 血液肿瘤学
  • 血液学
  • 神经病学
  • 呼吸系统医疗设备
  • 风湿病学

第八章血浆分馏市场：依最终用户分类

  • 介绍
  • 学术研究所
  • 临床研究实验室

第九章美洲血浆分馏市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太血浆分馏市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲/中东/非洲血浆分馏市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Grifols 埃及运送第一批由埃及捐赠血浆製成的血浆药物
    • CSL 耗资 4.7 亿美元的血浆分馏设施在德国马尔堡开业
    • 武田将投资 1,000 亿日圆在日本新血浆分馏产品生产设施
    • Kedrion 在沙乌地阿拉伯的血浆分馏研讨会上发表演讲
  • 战略分析和建议

公司名单

  • 3M Company
  • ADMA Biologics, Inc.
  • Bharat Serums and Vaccines Limited
  • Bio Products Laboratory Ltd.
  • BIoTest AG by Grifols, SA
  • China Biologic Products, Inc.
  • CSL Limited
  • Emergent BioSolutions Inc.
  • Fusion Health Care Pvt. Ltd.
  • GC Biopharma corp.
  • Grifols, SA
  • HEINKEL Process Technology GmbH
  • Hemarus Therapeutics Ltd
  • Intas Pharmaceuticals Ltd.
  • Kamada Ltd.
  • Kedrion SpA
  • LFB SA
  • Merck KGaA
  • Octapharma AG
  • PlasmaGen BioSciences Pvt. Ltd.
  • Prothya Biosolutions BV
  • Sanquin
  • Shanghai Raas Blood Products Co. Ltd
  • SK Plasma Co.,Ltd.
  • STERIS plc
  • Takeda Pharmaceutical Company Ltd
Product Code: MRR-4312A385A58A

The Plasma Fractionation Market was valued at USD 35.52 billion in 2023, expected to reach USD 38.95 billion in 2024, and is projected to grow at a CAGR of 10.45%, to USD 71.27 billion by 2030.

Plasma fractionation refers to the process of separating and purifying components of plasma, primarily used in medical therapies. This includes proteins such as immunoglobulins, albumin, and clotting factors that are essential for various therapeutic applications in treating conditions like immune deficiencies, hemophilia, and autoimmune disorders. The necessity of plasma fractionation arises from the critical need for plasma-derived therapies to manage chronic ailments that cannot otherwise be treated effectively with synthetic alternatives. As such, the primary application involves medicinal use, especially for diseases requiring long-term treatment. End-use sectors mainly include hospitals, research institutions, and pharmaceutical companies. The market is significantly influenced by increasing demand for personalized medicine, advancements in healthcare infrastructure, and rising awareness about plasma therapies. Technological advancements like improved plasma purification processes and integration of artificial intelligence in diagnostics present potential opportunities for growth. Key recommendations to seize these opportunities include investing in R&D to enhance product efficacy and forming strategic alliances to streamline supply chain processes. However, the market is constrained by factors such as the high cost of plasma therapies, ethical concerns regarding plasma donation, and stringent regulatory requirements across different regions. Moreover, fluctuations in plasma supply due to donors' availability can pose challenges in meeting global demand. Companies seeking growth should focus on areas like enhancing donor recruitment strategies and developing synthetic or alternative protein substitutes that could alleviate supply issues. Innovation could also be directed towards improving fractionation technologies to boost yield and safety standards. Given the competitive nature of the market, a thorough understanding of regulatory landscapes, and continuous investment in technological upgrades are essential for sustained success. Emphasis on education and awareness campaigns can also help mitigate donation concerns, ultimately supporting market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 35.52 billion
Estimated Year [2024] USD 38.95 billion
Forecast Year [2030] USD 71.27 billion
CAGR (%) 10.45%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Plasma Fractionation Market

The Plasma Fractionation Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Improving access to plasma-based therapies and high use of immunoglobulins in various therapeutic areas
    • Government initiatives to increase plasma collection
    • Growing prevalence of elderly people around the globe and the increasing number of blood collection facilities
  • Market Restraints
    • Presence of new pathogenic agents that resist the present viral inactivation treatments
  • Market Opportunities
    • Continuous advancements in process development technology for improved formulations
    • Exponential utilization in new clinical trials and growing R&D activities in plasma treatment
  • Market Challenges
    • Stringent government regulations on plasma fractionation and the presence of alternative recombinant therapies

Porter's Five Forces: A Strategic Tool for Navigating the Plasma Fractionation Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Plasma Fractionation Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Plasma Fractionation Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Plasma Fractionation Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Plasma Fractionation Market

A detailed market share analysis in the Plasma Fractionation Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Plasma Fractionation Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Plasma Fractionation Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Plasma Fractionation Market

A strategic analysis of the Plasma Fractionation Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Plasma Fractionation Market, highlighting leading vendors and their innovative profiles. These include 3M Company, ADMA Biologics, Inc., Bharat Serums and Vaccines Limited, Bio Products Laboratory Ltd., Biotest AG by Grifols, S.A., China Biologic Products, Inc., CSL Limited, Emergent BioSolutions Inc., Fusion Health Care Pvt. Ltd., GC Biopharma corp., Grifols, S.A., HEINKEL Process Technology GmbH, Hemarus Therapeutics Ltd, Intas Pharmaceuticals Ltd., Kamada Ltd., Kedrion S.p.A., LFB SA, Merck KGaA, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., Prothya Biosolutions B.V., Sanquin, Shanghai Raas Blood Products Co. Ltd, SK Plasma Co.,Ltd., STERIS plc, and Takeda Pharmaceutical Company Ltd.

Market Segmentation & Coverage

This research report categorizes the Plasma Fractionation Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Albumin, Coagulation Factor Concentrates, Immunoglobulin, and Protease Inhibitors. The Coagulation Factor Concentrates is further studied across Factor IX, Factor VIII, Factor XIII, Fibrinogen Concentrates, Prothrombin Complex Concentrate, and Von Willebrand Factor. The Immunoglobulin is further studied across Intravenous Immunoglobulin and Subcutaneous Immunoglobulin.
  • Based on Application, market is studied across Critical Care, Hemato-Oncology, Hematology, Neurology, Pulmonology, and Rheumatology.
  • Based on End-User, market is studied across Academic & Research Institutes and Clinical Research Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Improving access to plasma-based therapies and high use of immunoglobulins in various therapeutic areas
      • 5.1.1.2. Government initiatives to increase plasma collection
      • 5.1.1.3. Growing prevalence of elderly people around the globe and the increasing number of blood collection facilities
    • 5.1.2. Restraints
      • 5.1.2.1. Presence of new pathogenic agents that resist the present viral inactivation treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Continuous advancements in process development technology for improved formulations
      • 5.1.3.2. Exponential utilization in new clinical trials and growing R&D activities in plasma treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations on plasma fractionation and the presence of alternative recombinant therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising use of plasma fractionation for immunoglobulins purification
    • 5.2.2. Application: Proliferating use to treat hematological disorders
    • 5.2.3. End-User: Extensive use of plasma fractionation in clinical research laboratories to ensure the safety and efficacy of plasma-derived products
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Plasma Fractionation Market, by Product

  • 6.1. Introduction
  • 6.2. Albumin
  • 6.3. Coagulation Factor Concentrates
    • 6.3.1. Factor IX
    • 6.3.2. Factor VIII
    • 6.3.3. Factor XIII
    • 6.3.4. Fibrinogen Concentrates
    • 6.3.5. Prothrombin Complex Concentrate
    • 6.3.6. Von Willebrand Factor
  • 6.4. Immunoglobulin
    • 6.4.1. Intravenous Immunoglobulin
    • 6.4.2. Subcutaneous Immunoglobulin
  • 6.5. Protease Inhibitors

7. Plasma Fractionation Market, by Application

  • 7.1. Introduction
  • 7.2. Critical Care
  • 7.3. Hemato-Oncology
  • 7.4. Hematology
  • 7.5. Neurology
  • 7.6. Pulmonology
  • 7.7. Rheumatology

8. Plasma Fractionation Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic & Research Institutes
  • 8.3. Clinical Research Laboratories

9. Americas Plasma Fractionation Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Plasma Fractionation Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Plasma Fractionation Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Grifols Egypt delivers first plasma medicines made from Egyptian plasma donations
    • 12.3.2. CSL's USD470 Million Plasma Fractionation Facility Opens in Marburg, Germany
    • 12.3.3. Takeda to Invest 100 Billion JPY in a New Manufacturing Facility for Plasma-Derived Therapies in Japan
    • 12.3.4. Kedrion presented at plasma fractionation workshop in Saudi Arabia
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 3M Company
  • 2. ADMA Biologics, Inc.
  • 3. Bharat Serums and Vaccines Limited
  • 4. Bio Products Laboratory Ltd.
  • 5. Biotest AG by Grifols, S.A.
  • 6. China Biologic Products, Inc.
  • 7. CSL Limited
  • 8. Emergent BioSolutions Inc.
  • 9. Fusion Health Care Pvt. Ltd.
  • 10. GC Biopharma corp.
  • 11. Grifols, S.A.
  • 12. HEINKEL Process Technology GmbH
  • 13. Hemarus Therapeutics Ltd
  • 14. Intas Pharmaceuticals Ltd.
  • 15. Kamada Ltd.
  • 16. Kedrion S.p.A.
  • 17. LFB SA
  • 18. Merck KGaA
  • 19. Octapharma AG
  • 20. PlasmaGen BioSciences Pvt. Ltd.
  • 21. Prothya Biosolutions B.V.
  • 22. Sanquin
  • 23. Shanghai Raas Blood Products Co. Ltd
  • 24. SK Plasma Co.,Ltd.
  • 25. STERIS plc
  • 26. Takeda Pharmaceutical Company Ltd

LIST OF FIGURES

  • FIGURE 1. PLASMA FRACTIONATION MARKET RESEARCH PROCESS
  • FIGURE 2. PLASMA FRACTIONATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PLASMA FRACTIONATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. PLASMA FRACTIONATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PLASMA FRACTIONATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PLASMA FRACTIONATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PLASMA FRACTIONATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PLASMA FRACTIONATION MARKET DYNAMICS
  • TABLE 7. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY FACTOR IX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY FACTOR VIII, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY FACTOR XIII, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY FIBRINOGEN CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY VON WILLEBRAND FACTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CRITICAL CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATO-ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PULMONOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY RHEUMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CLINICAL RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 241. PLASMA FRACTIONATION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 242. PLASMA FRACTIONATION MARKET, FPNV POSITIONING MATRIX, 2023